Online Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 477 - Methods in Clinical Trials
Type: Contributed
Date/Time: Thursday, August 6, 2020 : 10:00 AM to 2:00 PM
Sponsor: Biometrics Section
Abstract #313967
Title: When to Re-Randomize in a Two-Part Study?
Author(s): Michelle DeVeaux* and Bret Musser
Companies: Regeneron Pharmaceuticals and Regeneron Pharmaceuticals
Keywords: re-randomization; stratification; two-part study; study design; dropout rate; sample size
Abstract:

Imagine a study with two parts. Part 1 of the study contains a randomization of patients to treatment arms A and B, followed by Part 2 with treatment arms C and D. The intent of the study design is to have a balanced number of patients at the end of the study who were randomized to receive the four possible combinations of treatments in Parts 1 and 2. Operationally, this can be done in two ways. Patients could be randomized to one of four arms defining both treatments assigned in Parts 1 and 2 at the initial randomization (patients randomized 1:1:1:1 to receive treatments A then B, A then C, B then C, and B then D in Parts 1 and 2, respectively). Alternatively, patients could be randomized to arms A or B and then re-randomized to arms C or D in Part 2 of the study, stratified by the treatment assigned in Part 1. While this corrects an imbalance in Part 1 due to dropouts, it also potentially creates new imbalances based on other factors. We will investigate the probability of treatment arm imbalance in these two scenarios under different assumptions. Simulations will be performed to examine the impact of sample size and dropout rate on the probability of imbalanced arms.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2020 program